These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 36847954)
1. Editorial on: Moving Beyond Anatomic Criteria for Resectability: Validation of the Anatomical and Biological Definitions of Borderline Resectable Pancreatic Cancer According to the 2017 International Consensus for Survival and Recurrence in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Upfront Surgery. Paniccia A; Zureikat A Ann Surg Oncol; 2023 Jun; 30(6):3184-3185. PubMed ID: 36847954 [No Abstract] [Full Text] [Related]
2. Validation of the Anatomical and Biological Definitions of Borderline Resectable Pancreatic Cancer According to the 2017 International Consensus for Survival and Recurrence in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Upfront Surgery. Lee B; Yoon YS; Kang M; Park Y; Lee E; Jo Y; Lee JS; Lee HW; Cho JY; Han HS Ann Surg Oncol; 2023 Jun; 30(6):3444-3454. PubMed ID: 36695994 [TBL] [Abstract][Full Text] [Related]
3. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Isaji S; Mizuno S; Windsor JA; Bassi C; Fernández-Del Castillo C; Hackert T; Hayasaki A; Katz MHG; Kim SW; Kishiwada M; Kitagawa H; Michalski CW; Wolfgang CL Pancreatology; 2018 Jan; 18(1):2-11. PubMed ID: 29191513 [TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant therapy versus upfront surgery in resectable pancreatic cancer: reconstructed patient-level meta-analysis of randomized clinical trials. Aliseda D; Martí-Cruchaga P; Zozaya G; Blanco N; Ponz M; Chopitea A; Rodríguez J; Castañón E; Pardo F; Rotellar F BJS Open; 2024 Sep; 8(5):. PubMed ID: 39329454 [TBL] [Abstract][Full Text] [Related]
5. "International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017": Will this pull us up out of the quagmire of confusing definitions and criteria? Takaori K Pancreatology; 2018 Jan; 18(1):1. PubMed ID: 29389525 [No Abstract] [Full Text] [Related]
6. Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study. Heinrich S; Besselink M; Moehler M; van Laethem JL; Ducreux M; Grimminger P; Mittler J; Lang H; Lutz MP; Lesurtel M; BMC Cancer; 2019 Jul; 19(1):675. PubMed ID: 31288786 [TBL] [Abstract][Full Text] [Related]
17. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma. Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998 [TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant therapy for localized pancreatic ductal adenocarcinoma. Brown ZJ; Shannon AH; Cloyd JM Minerva Surg; 2024 Jun; 79(3):315-325. PubMed ID: 38385797 [TBL] [Abstract][Full Text] [Related]
19. Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection. Marchegiani G; Todaro V; Boninsegna E; Negrelli R; Sureka B; Bonamini D; Salvia R; Manfredi R; Pozzi Mucelli R; Bassi C Eur Radiol; 2018 Oct; 28(10):4265-4273. PubMed ID: 29679211 [TBL] [Abstract][Full Text] [Related]
20. Clinical challenges associated with utility of neoadjuvant treatment in patients with pancreatic ductal adenocarcinoma. Gray S; de Liguori Carino N; Radhakrishna G; Lamarca A; Hubner RA; Valle JW; McNamara MG Eur J Surg Oncol; 2022 Jun; 48(6):1198-1208. PubMed ID: 35264307 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]